GlassScriptPhysician profile
Jonathan P Richard
NPI 1386676104
$1,722.17
in general payments reported to CMS, 2019-2025
28 companies · $283 in 2025
The $283 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $149 · 2020: $241 · 2021: $215 · 2022: $156 · 2023: $382 · 2024: $296 · 2025: $283.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $961.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $961.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $414.01 | 2019-2025 | Evenity, Repatha, Otezla |
| Antares Pharma, INC. | $170.92 | 2020-2024 | Xyosted, Tlando, Nocdurna |
| Pfizer INC. | $120.55 | 2024-2025 | |
| Abbvie INC. | $112.00 | 2019-2023 | |
| Azurity Pharmaceuticals, INC. | $104.95 | 2024-2025 | Horizant, Azmiro |
| Endo Pharmaceuticals INC. | $93.60 | 2019-2023 | Aveed |
| Lilly USA, LLC | $62.26 | 2023-2024 | Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $61.56 | 2022-2024 | Farxiga, Airsupra |
| Vbi Vaccine (Delaware) INC. | $51.86 | 2022-2023 | Prehevbrio |
| Novartis Pharmaceuticals Corporation | $47.84 | 2021-2025 | |
| Tolmar, INC. | $46.39 | 2023-2025 | Jatenzo |
| Abbott Laboratories | $43.28 | 2021-2022 | |
| Eisai INC. | $39.45 | 2020-2021 | |
| Endo USA, INC. | $39.18 | 2024-2025 | Aveed |
| Shire North American Group INC | $36.88 | 2019 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $33.25 | 2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Allergan, INC. | $31.96 | 2019 | |
| Glaxosmithkline, LLC. | $29.22 | 2023 | Shingrix |
| Novo Nordisk INC | $27.44 | 2022-2023 | Wegovy, Saxenda |
| Arbor Pharmaceuticals, INC. | $21.70 | 2019 | |
| Alvogen INC | $21.44 | 2022 | |
| Sumitomo Pharma America, INC. | $19.96 | 2023 | Gemtesa |
| Janssen Pharmaceuticals, INC | $19.82 | 2021 | |
| Halozyme INC | $16.88 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.44 | 2021 | |
| Acerus Pharmaceuticals Corporation | $15.77 | 2021 | |
| Radius Health, INC. | $12.25 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $11.31 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Richard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.